Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 94-32913 ...

Sarcomere Directed Therapies | --- | --- | --- | --- | |-------------------|-------|-------|-------| | | | | | | EMPOWERING | | | | | MUSCLE EMPOWERING | | | | | LIVES | | | | Nefertari, diagnosed with heart failure Jillian, diagnosed with HCM Chuck, diagnosed with ALS Actual patients who consented to use of their name, image, and condition. CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries Copyright©2022 CYTOKINETICS, All Rights Reserved F ...

Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2022 Earnings Conference Call August 4, 2022 4:30 AM ET Company Participants Diane Weiser - SVP, Corporate Communications and Investor Relations Robert Blum - President And Chief Executive Officer Fady Malik - EVP, Research and Development Andrew Callos - EVP, Chief Commercial Officer Stuart Kupfer - SVP, Chief Medical Officer Robert Wong - VP, Chief Accounting Officer Ching Jaw - SVP, Chief Financial Officer Conference Call Participants Justin Kim - Oppenheimer Y ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 94-3291317 (S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 Delaware 94-3291317 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Iden ...

Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Diane Weiser - SVP of Corporate Communications and IR Robert Blum - President and CEO Fady Malik - EVP of R&D Andrew Callos - EVP and Chief Commercial Officer Stuart Kupfer - SVP and Chief Medical Officer Robert Wong - VP and CAO Ching Jaw - SVP and CFO Conference Call Participants Carter Gould - Barclays Joe Pantginis - H.C. Wainwright Salim Syed - Mizuho Securities Sean McCutcheon - R ...

Sarcomere Directed Therapies | --- | --- | --- | --- | --- | --- | |-------------------|-------|-------|-------|-------|-------| | | | | | | | | EMPOWERING | | | | | | | MUSCLE EMPOWERING | | | | | | | LIVES | | | | | | Nefertari, diagnosed with heart failure Jillian, diagnosed with HCM Chuck, diagnosed with ALS Actual patients who consented to use of their name, image, and condition. CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries Copyri ...

Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Joanna Siegall - IR Robert Blum - President and CEO Fady Malik - EVP of R&D Stuart Kupfer - SVP and Chief Medical Officer Andrew Callos - CCO Robert Wong - VP and CAO Ching Jaw - SVP and CFO Conference Call Participants Carter Gould - Barclays Justin Kim - Oppenheimer Anupam Rama - JPMorgan Charles Duncan - Cantor Fitzgerald Robert Palermo - Goldman Sachs Melina Santoro - Morgan Stanle ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-50633 | --- | --- | |-------------------------------------------------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Common Stock, $0.001 par value Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 ...